Results 101 to 110 of about 5,090 (179)

Neutralizing monoclonal antibodies improve biodistribution of intravenously administered oncolytic adenovirus in human CD46-transgenic mice.

PLoS ONE
Oncolytic viruses are a unique modality with multifaceted mechanisms of action for killing cancer cells and have been developed as a promising therapeutic approach in cancer treatment. The first-in-class agent, talimogene laherparepvec (T-VEC), has shown
Masahisa Hemmi, Midori Yamashita, Yoshiko Shimizu, Shinsuke Nakao   +3 more
doaj   +1 more source

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma. [PDF]

JAAD Case Rep, 2023
Beekman KE, Parker LM, DePalo DK, Elleson KM, Sarnaik AA, Tsai KY, Withycombe BM, Zager JS.   +7 more
europepmc   +1 more source

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient. [PDF]

Case Rep Dermatol, 2023
Miller M, Kim NH, Thosani MK, Moser JC.
europepmc   +1 more source

Gyógyítható lesz-e a melanoma? Perspektívák a melanoma kezelésében = Will melanoma be curable? Perspectives in melanoma therapy [PDF]

, 2017
Baltás, Eszter, Gyulai, Rolland, Lengyel, Zsuzsanna   +2 more
core   +1 more source

Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma. [PDF]

Australas J Dermatol, 2022
Cilento MA, Klein O, Egan E, Roberts-Thomson R.   +3 more
europepmc   +1 more source

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. [PDF]

CPT Pharmacometrics Syst Pharmacol, 2023
Ahamadi M, Kast J, Chen PW, Huang X, Dutta S, Upreti VV.   +5 more
europepmc   +1 more source

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient

JAAD Case Reports, 2021
Kelsey E. Hirotsu, MD, Vivian Hua, BA, Anhthy T. Tran, MSN, Laura Morris, BSN, Sunil A. Reddy, MD, Bernice Y. Kwong, MD, Lisa C. Zaba, MD, PhD   +6 more
doaj   +1 more source

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study. [PDF]

J Am Acad Dermatol, 2023
Leung BW, Wan G, Nguyen N, Rashdan H, Zhang S, Chen W, Cohen S, Boland GM, Sullivan RJ, Fadden RM, Kaufman HL, Kwatra SG, LeBoeuf NR, Semenov YR.   +13 more
europepmc   +1 more source

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. [PDF]

ESMO Open, 2023
Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, Carrato A, Zhang Y, Liu K, Cha E, Keegan A, Bhatta S, Strassburg CP, Roohullah A.   +17 more
europepmc   +1 more source

Cancer immunotherapy: the beginning of the end of cancer? [PDF]

, 2016

core   +1 more source